Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
暂无分享,去创建一个
I. Flinn | R. Collins | P. Vyas | K. Yen | R. Levine | H. Kantarjian | M. Tallman | C. Dinardo | D. DeAngelo | R. Stone | S. de Botton | A. Fathi | M. Sekeres | J. Altman | A. Frankel | D. Pollyea | G. Roboz | S. Agresta | C. Willekens | E. Stein | R. Knight | R. Swords | A. Stein | B. Medeiros | Qiang Xu | A. Tosolini | M. Patel | R. Levine
[1] Hua Yang,et al. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. , 2017, Cancer discovery.
[2] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[3] Steven M. Chan,et al. Isocitrate dehydrogenase mutations in myeloid malignancies , 2016, Leukemia.
[4] C. Dinardo,et al. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. , 2016, Clinical lymphoma, myeloma & leukemia.
[5] O. Fiehn,et al. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate , 2016, eLife.
[6] J. Barnard,et al. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. , 2016, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.
[7] H. Kantarjian,et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression , 2015, Leukemia.
[8] M. Konopleva,et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML , 2015, American journal of hematology.
[9] A. Melnick,et al. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo , 2014 .
[10] E. Estey,et al. Management of older or unfit patients with acute myeloid leukemia , 2014, Leukemia.
[11] M. Gobbi,et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Sanz,et al. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. , 2014, Blood.
[13] P. Pandolfi,et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. , 2014, Cell stem cell.
[14] Claude Preudhomme,et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Fang Wang,et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.
[16] D. Margolis,et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. , 2012, Blood.
[17] E. Estey,et al. Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. , 2013, Clinical advances in hematology & oncology : H&O.
[18] D. Weisdorf,et al. Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.
[19] A. Iafrate,et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.
[20] M. Tallman,et al. How I treat hematologic emergencies in adults with acute leukemia. , 2012, Blood.
[21] M. Minden,et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[23] M. Tallman,et al. Curing all patients with acute promyelocytic leukemia: are we there yet? , 2011, Hematology/oncology clinics of North America.
[24] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[25] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[26] S. Larson,et al. Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.
[27] W. van Putten,et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. , 2010, Blood.
[28] Manuela Zucknick,et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Caligiuri,et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[31] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[32] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[33] E. Jantunen,et al. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences , 2008, Leukemia & lymphoma.
[34] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[36] C. Bloomfield,et al. All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .